QUEBEC CITY, May 20, 2015 /PRNewswire/ - DiagnoCure Inc. (TSX:
CUR; OTCQX: DGCRF) (the "Corporation") today reports that the
results of the prospective trial on its prostate cancer panel (PCP)
urine test were well received by the urologist community attending
the 2015 Annual Meeting of the American Urological Association
(AUA) held from May 15 to May 19 in
New Orleans, Louisiana.
DiagnoCure's presentation titled "Validated Urine-based
Multigene Signature for Detection of Aggressive Prostate
Cancer" had been chosen to be included in the 2015 AUA Press
Program about the use of imaging and urine-based biomarkers as ways
to improve prostate cancer detection. Following a rigorous
selection process, including a review by a panel of Public Media
Committee members and AUA Communications Department staff,
DiagnoCure's presentation was one of fewer than 45 presentations,
among more than 2,500 at this year's AUA annual meeting, selected
for discussion with the media. As part of this great honor, Dr.
Yves Fradet was given the
opportunity to speak with reporters about the PCP Risk Score at a
press conference held on Monday May 18,
2015.
The data presented highlight how the use of this new urine-based
test developed by Diagnocure can improve the detection of
higher-grade cancers to optimize clinical decisions relative to
first or repeat biopsies. An analysis of the performance of the PCP
Risk Score in the validation study (503 men) showed that one out of
three men had a PCP Risk Score greater than 60, and were classified
at very high risk of aggressive prostate cancer. Men with a score
less than 20 had only an 8 percent risk of high-grade disease.
"We believe that our new test which helps detect the potential
presence of prostate cancer as well as its aggressiveness was a
long awaited test in the clinical community. A number of tests are
currently available but few can really have this ability of
detecting non-invasively potentially lethal prostate cancers. That
information is critical for clinicians to decide if a biopsy is
needed. Our test can drastically change the way prostate cancer is
diagnosed and treated", stated Dr. Yves
Fradet, President and Chief Medical Officer of DiagnoCure.
He added: "This is particularly important at a time when
controversial recommendations have led to a decline in PSA
screening, and consequently, to an increased frequency of delayed
detection of advanced prostate cancers".
About the PCP Risk Score Test
The PCP Risk Score Test is the Corporation's newly developed
multimarker prostate cancer urine test to accurately identify risk
of aggressive cancer prior to biopsy. The test was developed and
validated in 764 men referred to prostate biopsy based on elevated
PSA. The PCP Risk Score test examined genes from multiple
biological pathways whose altered expression in urine was
associated with detection of aggressive prostate cancer.
Combination of this panel of urine-based biomarkers with
established risk factors (age, abnormal findings on rectal
examination or prior biopsy history) using a proprietary algorithm
allows calculation of the probability of finding an aggressive
prostate cancer. The resulting PCP Risk Score test thus provides
individualized risk assessment and adds new information that might
help physicians and their patients decide whether or not a prostate
biopsy is required.
About DiagnoCure
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences
corporation that develops and provides molecular and genomic tests
to support effective clinical decisions enabling personalized
medicine in oncology. Previstageâ GCC and the PCP
Risk Score test are currently available for licensing. The
Corporation has granted a worldwide exclusive license on the
diagnostic applications of PCA3 for the development and
commercialization of a prostate cancer test which is commercialized
in Europe under CE mark and
approved for commercialization in Canada and the
United States. For more information, please visit
www.diagnocure.com.
Forwardlooking statements
This release may contain forwardlooking statements that involve
known and unknown risks, uncertainties and assumptions that may
cause actual results to differ materially from those expected.
Forward-looking statements can be identified by the use of the
conditional or forward-looking terminology such as "anticipates",
"assumes", "believes", "estimates", "expects", "intend", "may",
"plans", "projects", "should", "will", or the negative thereof or
other variations thereon. Forward-looking statements also include
any other statements that do not refer to historical facts. All
such forward-looking statements are made pursuant to the
"safe-harbour" provisions of applicable Canadian securities laws.
By their very nature, forwardlooking statements are based on
expectations and assumptions and also involve risks and
uncertainties, known and unknown, many of which are beyond
DiagnoCure's control. Forward-looking statements are presented for
the purpose of assisting investors and others in understanding
certain key elements of the Corporation's current objectives,
strategic priorities, expectations and plans, and in obtaining a
better understanding of the Corporation's business and anticipated
operating environment. Readers are cautioned that such information
may not be appropriate for other purposes and that they should not
place undue reliance on these forwardlooking statements. For
instance, any forward-looking statements regarding the outcome of
research and development projects, clinical studies and future
revenues, including those related to PCP Risk Score are based on
management expectations and such outcome may vary materially
depending on global political and economic conditions, dependence
on collaboration partners, uncertainty of healthcare reimbursement,
and marketing and distribution challenges. In addition, the reader
is referred to the applicable general risks and uncertainties
described in DiagnoCure's most recent Annual Information Form under
the heading "Risk Factors". DiagnoCure undertakes no obligation to
publicly update or revise any forwardlooking statements contained
herein unless required by the applicable securities laws and
regulations.
SOURCE DiagnoCure inc.
